Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter s Q4 Revenues Fall 5.4 Percent as Income Drops 70 Percent

NEW YORK, Feb. 17 (GenomeWeb News) - Beckman Coulter reported today that its fourth-quarter sales fell by 5.4 percent to $655.5 million from $693 million during the year-ago period.

 

Fourth-quarter consumable sales were up 12 percent, with acquisitions contributing to 3.9 percent of that growth .

 

Net income for the period decreased 70 percent to $17.8 million from $59.8 million during the fourth quarter of 2004.

 

Beckman reaffirmed its outlook for 2006 that was stated on Nov. 2, 2005, when the company released its third quarter earnings report. Assuming stable currency, sales should be in the range of $2.53 billion to $2.60 billion, the company said.

 

For the first quarter of the year, sales should be $555 million to $575 million, Beckman said.

 

Beckman CEO Scott Garrett said he expects growth in 2006 to be led by placements of the company's DxC 600 and 800 Autochemistry platforms, and of the UniCel DxI 800 immunoassay systems.

 

Beckman did not break out its R&D spending for the fourth quarter or for the 2005 year.

 

As of Dec. 31, 2005, Beckman had $57.6 million in cash and cash equivalents.

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.